An important element of pregnancy screening is the screening of fetal chromosome aberrations. To determine this, we use the AFP test most often to date, even though we know for certain that the method does not give a reliable result.
Dr. Gyula CsermelyThe Rуzsakert Medical Center szьlйsz-nхgyуgyбsza said Magyarorszбgon terhessйgi szыrхvizsgбlatot the most commonly used, AFP vizsgбlatot vezettйk in ezelхtt forty йvvel, бm this eljбrбs you have already completely obsolete today szбmнt. Nowadays, in many countries, such a screening test is not conducted because it is so unreliable that it is unnecessary. We can say that the AFP test is totally inappropriate for screening for Down syndrome, and often misleading results frighten little babies. Gyula Csermely added: All risk analysis is based on the fact that the normal distribution curves of certain characteristics of patients and health differ from each other. However, in AFP screening, the normal distribution curves for AFP levels in healthy fetuses and in Down fetuses do not differ significantly. This means that the probability ratio of the test is low and many corpus luteum findings are produced. Unfortunately, because of the abnormal AFP results, in many cases, the baby is still being sent for amniotic fluid for accurate diagnosis, which, although accurate, results in a miscarriage at a frequency of 1 percent. The whole procedure takes weeks and puts a heavy burden on the pregnant mother. In addition to the Down kуr spina bifida is йs the open abdomen kiderнtйsйre only korlбtozottan for the AFP, as indicated by these rendellenessйgeket kцzvetetten, mнg the ultrasound kцzvetlenьl can be lбtni any eltйrйseket, sхt some cases (indoor spina bifida), AFP egyбltalбn not is capable of indicating even indirectly.Dr. Gyula Csermely went on to say: Today there is an excellent alternative to AFP screening, the so-called first trimester expanded screening, which carries a risk based on a blood sample and an abdominal ultrasound. This can only be done by well-equipped screening centers with FMF-accredited doctors. The probability rate of the test is over 90-95 percent, while 2-5 percent is the number of cases diagnosed with yeast. The AFP exam is conducted around week 16, and the expanded screening is significantly earlier, between weeks 11 and 13 of pregnancy. The test measures the results of cervical vertebrae, nasal bones, fetal facial nerve, venous conduction, and cardiac flow, supplemented by a biochemical examination of maternal blood. Cervical folds, beta-hCG, and PAPP-A measurements in the normal distribution curve differ significantly between the healthy and the patient population.